Indaptus Therapeutics publishes research in Frontiers in Immunology
The Fly

Indaptus Therapeutics publishes research in Frontiers in Immunology

Indaptus Therapeutics (INDP) announced that Dr. Michael Newman, Founder and Chief Scientific Officer, has published his research in the peer-reviewed journal, Frontiers in Immunology. The article, titled “Invention and Characterization of a Systemically Administered, Attenuated and Killed Bacteria-Based Multiple Immune Receptor Agonist for Antitumor Immunotherapy,” presents the Company’s innovative approach to activating both the innate and adaptive sides of the immune system to treat cancer. The paper is being published as part of a Research Topic on The Vital Role of Innate Immunity in Cancer Immunotherapy. Key Highlights from the Research: Multi-Pathway Immune Activation; Encouraging Preclinical Data; Reduced Toxicity Profile

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App